Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial

OBJECTIVES: Tocilizumab, an anti-IL-6 receptor antibody, was investigated in patients with refractory Takayasu arteritis (TAK) in a phase 3 randomized controlled trial. In this post hoc analysis, we investigated whether tocilizumab treatment inhibited the progression of vascular lesions caused by TA...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaoka, Yoshikazu, Yanagawa, Masahiro, Hata, Akinori, Yamashita, Katsuhisa, Okada, Norihiro, Yamakido, Shinji, Hayashi, Hiromitsu, Jayne, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157117/
https://www.ncbi.nlm.nih.gov/pubmed/34528074
http://dx.doi.org/10.1093/rheumatology/keab684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157117/
https://www.ncbi.nlm.nih.gov/pubmed/34528074
http://dx.doi.org/10.1093/rheumatology/keab684

Ejemplares similares